GlassScriptPhysician profile
Mark Maxilom Polintan
NPI 1306509971
$1,805.63
in general payments reported to CMS, 2019-2025
15 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $37.22 · 2024: $1,592 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,805.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $370.06 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $367.03 | 2024-2025 | |
| Novo Nordisk INC | $354.32 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $215.96 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Pfizer INC. | $95.75 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.54 | 2024-2025 | |
| Livanova USA, INC. | $67.36 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $50.34 | 2024 | Mounjaro, Jardiance, Zepbound |
| Hologic Sales and Service, LLC | $50.01 | 2024 | Thinprep 2000 Processor, Aptima |
| Astellas Pharma US INC | $43.19 | 2024 | Veozah |
| Dexcom, INC. | $33.81 | 2024 | Dexcom G6 Transmitter |
| Sage Therapeutics, LLC | $23.94 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $21.01 | 2024 | Quviviq |
| Exact Sciences Corporation | $14.78 | 2024 | Cologuard Collection Kit |
| Phadia US INC. | $13.53 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Polintan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.